Montelukast Sumar Pharma (Montelukast Sodium)

Montelukast Sodium acts as a selective antagonist of the cysteinyl leukotriene receptor CysLT1. By blocking this receptor, it prevents leukotriene D4 from triggering bronchoconstriction, mucus production, vascular leakage, and eosinophil recruitment, thereby reducing airway inflammation and hyper‑responsiveness.

The appropriate dose of Montelukast Sumar Pharma is determined by the prescribing healthcare professional based on the patient’s age, clinical condition, and response to therapy. Dosage instructions are provided on the prescription label and should be followed exactly as directed.

The safety of Montelukast Sumar Pharma in pregnancy and lactation has not been definitively established. Healthcare providers weigh potential benefits against possible risks before prescribing it to pregnant or nursing individuals, and patients should discuss any concerns with their clinician.

To request Montelukast Sumar Pharma, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It is particularly useful for patients with aspirin‑exacerbated respiratory disease or those who prefer a once‑daily tablet, but it may be less potent than inhaled steroids for severe asthma control.

Montelukast Sumar Pharma should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Montelukast Sumar Pharma is taken orally, usually as a tablet, with or without food. The medication is typically taken once daily in the evening, but the exact timing and administration instructions are provided by the prescribing clinician.

Serious adverse reactions, although rare, include angioedema, severe skin reactions such as Stevens‑Johnson syndrome, eosinophilic granulomatosis with polyangiitis, hepatic injury, anaphylaxis, and neuropsychiatric events like depression or suicidal thoughts. Patients should seek immediate medical attention if any of these occur.

Montelukast Sumar Pharma should be avoided in individuals with a known hypersensitivity to montelukast or any of its excipients. It is also contraindicated in patients who have experienced severe allergic reactions to leukotriene‑modifying agents. Clinicians should assess each patient’s medical history before initiating therapy.